Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases.

Federico CarboneGiorgia BodiniMatteo BrunacciAldo BonaventuraAlessandra VecchièLuca LiberaleMattia CrespiIsabella BaldissarroFranco DallegriVincenzo SavarinoFabrizio MontecuccoEdoardo G Giannini

Published in: European journal of clinical investigation (2018)

This study indicates TIMP-2 reduction during IBD treatment with monoclonal anti-TNF-α antibodies as a potential prognostic parameter of short and long term remission. To understand if TIMP-2 is an innocent biomarker or an active pathophysiological factor in IBD remains to be clarified.

Keyphrases

ulcerative colitis
disease activity
rheumatoid arthritis
systemic lupus erythematosus
combination therapy
human health